Skip to main content

Table 1 Characteristics of included studies

From: Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database

Study

Year

Author's country

Sample Size, N

Male, N(%)

Age, Years, Mean ± SD or Median(IQR)

Baseline eGFR,

mL/min/1.73 m2,

Mean ± SD or Median(IQR)

ICIs-related AKI, N (%)

Cases underwent renal biopsy, N (%)

Meraz-Muñoz [10]

2020

Canada

309

186(60.2)

61(51–69)

88(75–99)

51(16.5)

6(11.8)

Abdelrahim [3]

2021

USA

1664

1098(66.0)

NA

NA

72(4.3)

25(34.7)

Seethapathy [5]

2019

USA

1016

616(60.6)

63 ± 13

82 ± 22

169(16.6)

1(0.6)

Cortazar [9]

2020

USA

414

254(61.4)

NA

NA

138(33.3)

60(43.5)

Koks [4]

2021

Netherlands

676

420(62.1)

64(53–71)

90(75–101)

96(14.2)

1 (1.0)

Shimamura [13]

2021

Japan

152

114(75.0)

67 ± 10

72(55–87)

27(17.8)

1 (3.7)

Stein [11]

2020

France

239

132(55.2)

68(58.5–77)

84(70–94)

41(17.1)

3(7.3)

Seethapathy [12]

2020

USA

599

298(49.7)

65 ± 13

88 ± 26

36(6.0)

1(2.8)

Gupta [14]

2021

USA

858

517(60.3)

NA

NA

429(50.0)

151(35.2)

  1. ICI Immune checkpoint inhibitor, AKI Acute kidney injury, SD Standard deviation, IQR Interquartile range, NA Not available